Medtronic completes $650 million SPR acquisition, escalating competition in neuromodulation market

Medtronic Completes $650 Million SPR Acquisition, Escalating Battle in Neuromodulation Market

Medtronic announced on July 16, 2026, the completion of its acquisition of SPR Therapeutics for approximately $650 million. The deal brings SPR's FDA-approved Sprint Peripheral Nerve Stimulation system into Medtronic's neuromodulation portfolio, marking another significant move by the medical technology giant in the non-opioid pain treatment space.

Industry Background: Neuromodulation Becomes a Battleground for MedTech Giants

Neuromodulation is one of the fastest-growing segments in the medical device market in recent years. Medtronic CFO Thierry Piéton defined it as a "strategic focus and investment area" during the company's June earnings call, noting that the market is growing at over 20% annually. Against the backdrop of the ongoing global opioid crisis and healthcare systems seeking non-pharmacological pain management solutions, neuromodulation technology is expanding from traditional spinal cord stimulation toward earlier, less invasive interventions. SPR's Sprint device fits precisely into this demand—it provides 60-day peripheral nerve stimulation via temporarily implanted electrodes, avoiding the risks and costs of permanent implants.

Key Developments: Sprint's Clinical Evidence and Market Positioning

• The Sprint system first received FDA 510(k) clearance in 2017, initially with a 30-day treatment period, later extended to 60 days. Its clinical evidence base is continuously improving:
• A 2026 multicenter clinical trial co-funded by the U.S. Department of Defense and SPR showed that, for patients with chronic low back pain, Sprint achieved statistically significant pain relief at 3 months compared to standard interventional treatment (published in *Pain Medicine*).
• A 2025 study funded by SPR reported that treatment benefits could be sustained up to a 5-year follow-up period (published in *Pain and Therapy*).
• Pooled results from 13 studies showed that 60% of patients experienced ≥50% pain reduction at the end of the 60-day treatment.

These data position Sprint uniquely as an "early intervention" tool in the chronic pain treatment pathway—offering a minimally invasive, reversible option after conservative treatment fails but before permanent implantation or surgery. Medtronic explicitly positions Sprint as a tool to "intervene earlier in chronic pain management."

Market Impact: M&A Acceleration and Competitive Landscape ReshapingMedtronic's acquisition is not an isolated event. In the first half of 2026, Medtronic completed several acquisitions exceeding $500 million, including the $585 million acquisition of CathWorks (coronary physiology assessment) and the $550 million acquisition of Scientia Vascular (neurovascular interventional devices). In the neuromodulation field, Medtronic also signed a distribution agreement with Merit Medical for the ViaVerte basivertebral nerve ablation system. Piéton stated at the Leerink event in March that the company has decided to 'regain offensive momentum in M&A,' with transaction sizes of $100 million to $300 million being the 'sweet spot.'

This series of actions indicates that under the pressure of volume-based procurement, the impact of emerging technologies, and strong patient demand for non-opioid therapies, large device companies are rapidly acquiring differentiated technologies through M&A to fill product line gaps. The addition of SPR gives Medtronic a full-process capability in chronic pain treatment, ranging from early minimally invasive (Sprint) to mid-stage ablation (ViaVerte) to late-stage implantation (traditional neurostimulators).

Challenges and Risks

• Despite optimistic prospects, Sprint's commercialization still faces several obstacles:
• Reimbursement pathway: As a 60-day temporary therapy, Sprint currently mainly relies on out-of-pocket or commercial insurance, and coverage by Medicare and Medicaid is not yet clear.
• Competitive pressure: Rivals such as Boston Scientific and Abbott are also active in the neuromodulation field and already have similar temporary nerve stimulation products.
• Clinical adoption: Physicians' acceptance of the 60-day treatment course, patient follow-up management, and the need for re-treatment still require long-term validation.
• Regulatory changes: CMS recently proposed canceling the add-on payment path for breakthrough devices (NTAP), which may affect hospitals' willingness to adopt innovative devices.

Future Outlook: The 'Lightweight' Trend in Neuromodulation

In the next 3-5 years, the neuromodulation market will show two major trends: first, devices evolving towards smaller, more temporary, and more accessible directions, with Sprint being a representative of this trend; second, the integration of AI and digital health technologies, such as using wearable sensors to monitor stimulation effects and automatically adjust parameters. Medtronic already has AI algorithm expertise in the pacemaker field and is expected to deploy similar capabilities to the pain management product line in the future. M&A itself is also a sign of capital flowing back to high-growth areas—after the M&A trough in 2023-2024, transaction activity in the medical device industry is recovering.

ConclusionMedtronic's acquisition of SPR is not just a supplement to its product portfolio, but also a bet on the direction of technological evolution in the neuromodulation field. As the demand for non-opioid pain management intensifies, clinical evidence for minimally invasive techniques accumulates, and payers place greater emphasis on value-based healthcare, lightweight neuromodulation devices like Sprint are poised to change the treatment paradigm for chronic pain. This deal once again confirms the strategic shift of medical device giants: instead of relying solely on internal R&D, they are quickly entering the fastest-growing segments through precise acquisitions.

In the future, competition in the neuromodulation market will depend not only on the iteration of traditional electrical stimulation technologies, but also on who can first provide complete solutions from early intervention to long-term management—and Medtronic is trying to take a key step through this acquisition.